News and developments
Discover all the information about the research, development and marketing of immunotherapy treatments and natural food supplements for a healthier life.
15/01/2026
Probelte Pharma SL was awarded a grant from the Murcia Regional Development Agency’s grant programme to encourage SMEs in the region to procure innovation and competitiveness services, co-funded by the European Regional Development Fund. File: 2024.08.hino.000112
The aim of this project was to promote a more efficient business environment, helping to deliver the benefits of tax credits to support business innovation
01/12/2025
Probelte Pharma published the protocol for the PROACAROS phase III Beltavac® clinical trial in the TRIALS journal
Murcia, Spain — May 2025 Probelte Pharma has announced that the full protocol for the PROACAROS phase III clinical trial, designed to evaluate the efficacy and safety of Beltavac® subcutaneous…
30/09/2025
Publication of findings on subcutaneous immunotherapy in the paediatric population
On 12 June, a study on the Beltavac® preparation was published in the Journal of Clinical Medicine, demonstrating the efficacy and good safety profile of subcutaneous immunotherapy in paediatric…
10/12/2024
"Internationalisation Mentoring and Support” Programme
Probelte Pharma SLU, has received funding from the SME Internationalisation Mentoring and Support Programme. Among other costs, the company has used these funds to jointly fund dissemination and…
06/03/2024
Probelte Pharma awarded the Plimsoll Certificate of Business Excellence 2023
Probelte Pharma SL, a manufacturer of allergen and bacterial immunotherapy products, has been awarded the Plimsoll Certificate of Business Excellence 2023. According to its latest…
17/10/2023
Evaluation of the efficacy of subcutaneous immunotherapy with polymerised allergenic extract from Dermatophagoides pteronyssinus in patients with hypersensitivity to house dust mites
PROBELTE PHARMA has participated in the project entitled "EVALUATION OF THE EFFICACY OF SUBCUTANEOUSIMMUNOTHERAPY WITH POLYMERISED ALLERGENIC EXTRACT FROM DERMATOPHAGOIDES PTERONYSSINUS…
16/03/2023
Murcia Chamber of Commerce XPANDE Programme
Probelte Pharma, S.L. has been a beneficiary of the European Regional Development Fund (ERDF), whose objective is to improve the competitiveness of SMEs. Thanks to this, we launched an…
